Skip to main content

Drug Interactions between estramustine and hyaluronidase / rituximab

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

estramustine hyaluronidase

Applies to: estramustine and hyaluronidase / rituximab

Larger amounts of hyaluronidase may be required to achieve equivalent dispersing effects if patients are concomitantly receiving large doses of salicylates, cortisone, ACTH, estrogens, or antihistamines. These drugs may render tissues partially resistant to the dispersing action of hyaluronidase.

References

  1. (2004) "Product Information. Vitrase (hyaluronidase)." Bausch and Lomb Americas, Inc.
  2. (2018) "Product Information. Hylenex (hyaluronidase)." Halozyme Therapeutics
  3. (2023) "Product Information. Vyvgart Hytrulo (efgartigimod alfa-hyaluronidase)." argenx US Inc.

Switch to consumer interaction data

Drug and food interactions

Moderate

estramustine food

Applies to: estramustine

ADJUST DOSING INTERVAL: Food and milk may significantly decrease serum concentrations of estramustine. The mechanism of the interaction is not known.

MANAGEMENT: It is recommended that estramustine be taken at least 1 hour before or 2 hours after meals, and that it not be coadministered with milk, or calcium containing products.

References

  1. (2001) "Product Information. Emcyt (estramustine)." Pharmacia and Upjohn

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer